The FDA has approved Byooviz as a biosimilar to Lucentis for the treatment of some retinal diseases and conditions, including wet age-related macular degeneration, according to a press release from Samsung Bioepis and Biogen.
Byooviz (ranibizumab-nuna) is the first ophthalmology biosimilar to receive FDA approval. Other indications include the treatment of macular edema following retinal vein occlusion and myopic choroidal neovascularization.
“In the United States, approximately 11 million people are affected with AMD, and the prevalence of advanced AMD is growing due to the aging